Reliability and Validity of an Iranian Version of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for Patients with Multiple Myeloma: the EORTC QLQ-MY20

  • Ahmadzadeh, Ahmad (Research Centre of Cancer, Shafa Hospital, Ahvaz Jundishapur University of Medical Science) ;
  • Yekaninejad, Mir Saeed (Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences) ;
  • Saffari, Mohsen (Health Research Center, Baqiyatallah University of Medical Sciences) ;
  • Pakpour, Amir H (Social Determinants of Health Research Center, Qazvin University of Medical Sciences) ;
  • Aaronson, Neil K (Division of Psychosocial Research & Epidemiology, The Netherlands Cancer Institute)
  • Published : 2016.02.05


Background: Reliable and validated instruments are needed in order to study the quality of life in myeloma patients. This study aimed to translate and explore the psychometric properties of the European Organisation for Research and Treatment of Cancer (EORTC) myeloma module (QLQ-MY20) in Iranian patients. Materials and Methods: Two hundred and fifteen patients with multiple myeloma (MM) were recruited from Imam Khomeini Hospital, Tehran. A standard forward-backward translation procedure was implemented. Participating patients were asked to complete the EORTC QLQ-C30 and the QLQ-MY20 three times, at study entry, after two weeks, and again after three months. Data were tested for the range of measurement, internal consistency, test-retest reliability, known group comparison, responsiveness and factor structure. Results: Mean age of the patients was 60.7 years. No floor and ceiling effects were seen for the QLQ-MY20. Cronbach's ${\alpha}$ was greater than 0.80 for all three multi-item scales (ranging from 0.82 to 0.93). All four scales had test-retest reliability of 0.85 or greater. Results of the confirmatory factor analysis that the hypothesized 3-scale measurement model of the QLQ-MY20. Moreover, the Persian version for the QLQ-MY20 differentiated between subgroups of the patients in terms of beta-2 microglobulin, fracture and performance status. The responsiveness of the QLQ-MY20 to change over time was confirmed within 3 months. Conclusions: the results of our study indicate that our Iranian version of the QLQ-MY20 is a feasible, reliable and valid questionnaire for assessing the condition-specific quality of life of patients with MM.


Quality of life;validation;EORTC QLQ-MY20;cancer;outcome assessment;psychometrics;Iran


  1. Aaronson NK, Ahmedzai S, Bergman B, et al (1993). The european organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst, 85, 365-76.
  2. Alexanian R, Dimopoulos M (1994). The treatment of multiple myeloma. N Engl J Med, 330, 484-9.
  3. Attal M, Harousseau JL, Stoppa AM, et al (1996). A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. intergroupe francais du myelome. N Engl J Med, 335, 91-7.
  4. Benjamini Y, Krieger AM, Yekutieli D (2006). Adaptive linear step-up procedures that control the false discovery rate. Biometrika, 93, 491-507.
  5. Cocks K, Cohen D, Wisloff F, et al (2007). An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma. Eur J Cancer, 43, 1670-8.
  6. Greipp PR, Lust JA, O'Fallon WM, et al (1993). Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood, 81, 3382-7.
  7. Guise TA (2006). Bone loss and fracture risk associated with cancer therapy. Oncologist, 11, 1121-31.
  8. Hair JF, Black WC, Babin BJ, et al (2010). Multivariate data analysis: a global prospective Boston, Pearson Education.
  9. Jemal A, Tiwari RC, Murray T, et al (2004). Cancer statistics, 2004. CA Cancer J Clin, 54, 8-29.
  10. Johnsen AT, Tholstrup D, Petersen MA, et al (2009). Health related quality of life in a nationally representative sample of haematological patients. Eur J Haematol, 83, 139-48.
  11. Kontodimopoulos N, Samartzis A, Papadopoulos AA, et al (2012). Reliability and validity of the Greek QLQ-C30 and QLQ-MY20 for measuring quality of life in patients with multiple myeloma. Scientific World J, 2012, 842867.
  12. Kvam AK, Fayers P, Hjermstad M, et al (2009). Health-related quality of life assessment in randomised controlled trials in multiple myeloma: a critical review of methodology and impact on treatment recommendations. Eur J Haematol, 83, 279-89.
  13. Kyle RA, Rajkumar SV (2004). Multiple myeloma. N Engl J Med, 351, 1860-73.
  14. Liang MH, Fossel AH, Larson MG (1990). Comparisons of five health status instruments for orthopedic evaluation. Med Care, 28, 632-42.
  15. Montazeri A, Harirchi I, Vahdani M, et al (1999). The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30): translation and validation study of the Iranian version. Support Care Cancer, 7, 400-6.
  16. Osborne TR, Ramsenthaler C, Siegert RJ, et al (2012). What issues matter most to people with multiple myeloma and how well are we measuring them? A systematic review of quality of life tools. Eur J Haematol, 89, 437-57.
  17. Rosner B (1995). Fundamentals of Biostatitistcs, Belmont, CA, Duxbury Press.
  18. Sonmez M, Akagun T, Topbas M, et al (2008). Effect of pathologic fractures on survival in multiple myeloma patients: a case control study. J Exp Clin Cancer Res, 27, 11.
  19. Terwee CB, Bot SD, de Boer MR, et al (2007). Quality criteria were proposed for measurement properties of health status questionnaires. J Clin Epidemiol, 60, 34-42.
  20. Wisloff F, Hjorth M (1997). Health-related quality of life assessed before and during chemotherapy predicts for survival in multiple myeloma. nordic myeloma study group. Br J Haematol, 97, 29-37.